Your browser is no longer supported. Please, upgrade your browser.
AKCA Akcea Therapeutics, Inc. daily Stock Chart
AKCA [NASD]
Akcea Therapeutics, Inc.
Index- P/E- EPS (ttm)-0.08 Insider Own76.80% Shs Outstand100.52M Perf Week9.32%
Market Cap1.46B Forward P/E- EPS next Y-2.13 Insider Trans-0.02% Shs Float16.90M Perf Month-16.14%
Income40.80M PEG- EPS next Q-0.46 Inst Own21.00% Short Float19.92% Perf Quarter-13.50%
Sales488.50M P/S2.99 EPS this Y115.80% Inst Trans0.05% Short Ratio12.26 Perf Half Y-3.90%
Book/sh3.34 P/B4.36 EPS next Y-10.40% ROA8.70% Target Price30.00 Perf Year-53.05%
Cash/sh4.61 P/C3.15 EPS next 5Y- ROE10.00% 52W Range8.00 - 32.57 Perf YTD-14.11%
Dividend- P/FCF7.01 EPS past 5Y19.40% ROI6.60% 52W High-55.33% Beta-
Dividend %- Quick Ratio11.60 Sales past 5Y- Gross Margin96.80% 52W Low81.88% ATR1.46
Employees294 Current Ratio11.80 Sales Q/Q2621.20% Oper. Margin7.80% RSI (14)51.24 Volatility8.27% 13.97%
OptionableYes Debt/Eq0.00 EPS Q/Q164.00% Profit Margin8.30% Rel Volume0.67 Prev Close14.47
ShortableYes LT Debt/Eq0.00 EarningsFeb 25 AMC Payout- Avg Volume274.50K Price14.55
Recom2.40 SMA209.40% SMA50-8.76% SMA200-23.14% Volume183,452 Change0.55%
Oct-07-19Upgrade Wells Fargo Market Perform → Outperform
Sep-23-19Downgrade Wells Fargo Outperform → Market Perform $44 → $24
Sep-18-18Initiated Needham Buy $45
Aug-07-18Reiterated Stifel Hold $33
May-11-18Upgrade Wells Fargo Market Perform → Outperform
Mar-19-18Downgrade Wells Fargo Outperform → Market Perform
Mar-15-18Upgrade Wells Fargo Market Perform → Outperform
Feb-27-18Downgrade Wells Fargo Outperform → Market Perform
Feb-27-18Downgrade Stifel Buy → Hold $20
Nov-07-17Reiterated Stifel Buy $19 → $20
Mar-31-20 07:10AM  Lawsuit for Investors in Akcea Therapeutics, Inc. (NASDAQ: AKCA) shares announced by Shareholders Foundation GlobeNewswire
Mar-25-20 08:16AM  New Strong Sell Stocks for March 25th Zacks
Mar-24-20 07:00AM  Akcea Therapeutics Announces Appointment of Dr. Damien McDevitt as CEO GlobeNewswire +11.37%
Mar-18-20 10:12AM  New Strong Sell Stocks for March 18th Zacks
Mar-13-20 07:00AM  Akcea Therapeutics Canada celebrates official launch of first-of-its-kind research grant program CNW Group +6.20%
Mar-11-20 07:00AM  Dr. Lisa Johnson-Pratt Joins Akcea Therapeutics as Senior Vice President, New Product Strategy; Joshua Patterson promoted to General Counsel, adding to the companys leadership team GlobeNewswire -8.01%
Mar-09-20 05:19AM  New Strong Sell Stocks for March 9th Zacks -15.49%
Feb-28-20 07:00AM  Akcea Supports Rare Disease Day 2020 and Global Efforts to Reframe Rare GlobeNewswire
Feb-27-20 07:55AM  Akcea Therapeutics, Inc. Just Recorded A 13% Earnings Beat: Here's What Analysts Think Simply Wall St. -8.59%
Feb-26-20 07:00AM  Akcea Therapeutics to Present at the Cowen 40th Annual Health Care Conference GlobeNewswire
Feb-25-20 04:05PM  Akcea Reports Financial Results and Highlights for Fourth Quarter and Year End 2019 GlobeNewswire
Feb-18-20 07:00AM  Akcea Therapeutics to Hold Fourth Quarter and Full Year 2019 Financial Results Webcast GlobeNewswire
Feb-13-20 07:00AM  Akcea Expands Board of Directors with Appointment of Dr. Amber Salzman GlobeNewswire
Jan-28-20 04:05PM  Akcea and Ionis report positive topline phase 2 study results of AKCEA-ANGPTL3-LRx GlobeNewswire
Jan-23-20 10:35AM  Company News for Jan 23, 2020 Zacks
Jan-22-20 04:29PM  Will These Biotechs Rival A Top-Notch Stock In High Triglycerides? Investor's Business Daily +10.96%
07:05AM  Akcea and Ionis report positive topline Phase 2 results of AKCEA-APOCIII-L Rx PR Newswire
Jan-17-20 05:23AM  The Akcea Therapeutics (NASDAQ:AKCA) Share Price Is Down 41% So Some Shareholders Are Getting Worried Simply Wall St.
Jan-10-20 07:00AM  Akcea and Ionis Announce Initiation of CARDIO-TTRansform Phase 3 Clinical Trial for AKCEA-TTR-LRx in Patients with TTR-mediated Amyloid Cardiomyopathy GlobeNewswire
Jan-02-20 08:00AM  New England Journal of Medicine Publishes Results from Phase 2 Study of AKCEA-APO(a)-LRx in Patients with Lp(a)-driven Cardiovascular Disease GlobeNewswire
Dec-23-19 03:59PM  Hedge Funds Are Selling Akcea Therapeutics, Inc. (AKCA) Insider Monkey
Dec-19-19 07:52AM  The Daily Biotech Pulse: Seattle Genetics' Bladder Cancer Drug Gets FDA Nod, Paratek Wins Contract For Antibiotic Benzinga
Dec-18-19 10:03PM  Akcea Retains Rights to AKCEA-APOCIII-LRx GlobeNewswire
Dec-16-19 07:00AM  Akcea Therapeutics Announces New Appointments to its Board of Directors GlobeNewswire +6.79%
Dec-06-19 08:00AM  12 Biotech Stocks Primed For A Short Squeeze Benzinga
Dec-04-19 07:00AM  Akcea Announces Appointment of New Chief Operating Officer GlobeNewswire +6.66%
Nov-25-19 07:00AM  Akcea and Ionis Announce Initiation of NEURO-TTRansform Phase 3 Clinical Trial for AKCEA-TTR-LRx in Patients with Polyneuropathy Driven by Hereditary TTR Amyloidosis GlobeNewswire
Nov-20-19 07:25AM  The Daily Biotech Pulse: Endo's Cellulite Treatment Accepted For Review, Diffusion Pharma Reports Positive Glioblastoma Data Benzinga +8.18%
Nov-19-19 04:05PM  Akcea and Ionis Announce Closing of Licensing Agreement with Pfizer Inc. for Investigative Antisense Therapy AKCEA-ANGPTL3-L(Rx) GlobeNewswire
Nov-18-19 06:06AM  Here's Why We're Not At All Concerned With Akcea Therapeutics's (NASDAQ:AKCA) Cash Burn Situation Simply Wall St.
Nov-13-19 07:00AM  Akcea Therapeutics to Present at Upcoming Investor Conferences GlobeNewswire
Nov-07-19 06:07AM  3 Biotech Stocks Needham Expects to Double in the Next 12 Months TipRanks
Nov-05-19 06:25PM  Akcea Therapeutics (AKCA) Reports Q3 Loss, Tops Revenue Estimates Zacks
04:05PM  Akcea Reports Financial Results and Highlights for Third Quarter 2019 GlobeNewswire
06:53AM  The Daily Biotech Pulse: FDA Nod For Sanofi, BioCryst's Edema Drug In Japan, Myriad's Q1 Disappointment Benzinga
Nov-01-19 07:00AM  Akcea Recognizes Landmark Year for Familial Chylomicronemia Syndrome (FCS) Community with Commemoration of 2nd Annual FCS Awareness Day GlobeNewswire
Oct-29-19 10:32AM  Will Akcea Therapeutics (AKCA) Report Negative Earnings Next Week? What You Should Know Zacks
Oct-25-19 09:00AM  Akcea Therapeutics (AKCA) Upgraded to Strong Buy: Here's Why Zacks
Oct-23-19 07:00AM  Akcea Announces Appointment of New Chief Commercial Officer GlobeNewswire
Oct-22-19 07:00AM  Akcea Therapeutics to Hold Third Quarter 2019 Financial Results Webcast GlobeNewswire
Oct-21-19 11:30AM  Hedge Funds Have Never Been This Bullish On Akcea Therapeutics, Inc. (AKCA) Insider Monkey
Oct-18-19 08:54AM  What's in Store for Align Technology's (ALGN) Q3 Earnings? Zacks
Oct-17-19 12:03PM  Will New Alliances Aid Quest Diagnostics (DGX) Q3 Earnings? Zacks
10:21AM  Can Sequencing Products Drive Illumina's (ILMN) Q3 Earnings? Zacks
07:22AM  What's in Store for Edwards Lifesciences' (EW) Q3 Earnings? Zacks
Oct-15-19 10:37AM  Can Structural Heart Strength Aid Abbott (ABT) Q3 Earnings? Zacks
Oct-14-19 11:43AM  Can Balanced Segmental Growth Aid Abbott (ABT) Q3 Earnings? Zacks
Oct-09-19 11:18AM  Biotech Stock Roundup: GILD's Descovy Label Expansion Gets FDA Nod & Other Updates Zacks
Oct-07-19 04:13PM  How A Deal With Pfizer Sent This Pharma Stock Rocketing In High Volume Investor's Business Daily +31.33%
08:06AM  Akcea Stocks Soars on Pfizer Licensing Agreement TheStreet.com
06:50AM  Akcea and Pfizer Inc. Announce Licensing Agreement for investigative antisense therapy AKCEA-ANGPTL3-L(Rx) GlobeNewswire
Oct-01-19 09:11AM  Akcea Therapeutics Enters Oversold Territory Zacks
Sep-24-19 08:12AM  The Daily Biotech Pulse: Sandoz Recalls Ulcer Drug, Anchiano Strikes Agreement With ADT Pharma, Proteon Announces Reverse Merger Benzinga
Sep-23-19 09:43AM  Akcea's stock drops after 3 top executives leave company, including CEO MarketWatch -19.70%
09:40AM  Akcea Therapeutics shakes up executive suite, board in 'disconcerting' move American City Business Journals
07:15AM  [video]Akcea Shares Sink as Three Top Executives Leave the Biopharma TheStreet.com
07:00AM  Akcea Announces CEO Transition and Elects Two New Board Members GlobeNewswire
Sep-19-19 06:43AM  Does Market Volatility Impact Akcea Therapeutics, Inc.'s (NASDAQ:AKCA) Share Price? Simply Wall St.
Sep-16-19 07:00AM  Positive Phase 1 Results of AKCEA-TTR-LRx Presented at the Heart Failure Society of America Annual Meeting GlobeNewswire +6.06%
Aug-29-19 07:00AM  Akcea and Ionis to Present New Data for TEGSEDI and AKCEA-TTR-LRx at Two Upcoming Medical Meetings GlobeNewswire
Aug-14-19 01:47PM  Ionis Pharmaceuticals Looks to Partners to Pay the Bills Motley Fool
Aug-07-19 05:10PM  New England Journal of Medicine Publishes Results from Pivotal Study of WAYLIVRA® (volanesorsen) in Patients with Familial Chylomicronemia Syndrome GlobeNewswire +5.52%
08:24AM  Akcea Therapeutics, Inc. (AKCA) Q2 2019 Earnings Call Transcript Motley Fool
Aug-06-19 07:55PM  Akcea Therapeutics (AKCA) Reports Q2 Loss, Misses Revenue Estimates Zacks
04:05PM  Akcea Reports Financial Results and Highlights for Second Quarter 2019 GlobeNewswire
04:05PM  Akcea and Ionis Report Top-line Results from the BROADEN Study with WAYLIVRA® (volanesorsen) in Patients with Familial Partial Lipodystrophy GlobeNewswire
Jul-30-19 10:38AM  Will Akcea Therapeutics (AKCA) Report Negative Earnings Next Week? What You Should Know Zacks
Jul-29-19 07:00AM  Akcea Therapeutics to Hold Second Quarter 2019 Financial Results Webcast GlobeNewswire
Jul-16-19 07:00AM  hATTR Compass Genetic Testing Program Continues to Expand and Enable Diagnosis and Treatment of Hereditary ATTR Amyloidosis One Year Following Launch GlobeNewswire
Jun-26-19 07:00AM  Akcea and Ionis Announce Upcoming Data Presentations at the 5th European Academy of Neurology Annual Congress GlobeNewswire
Jun-21-19 08:27AM  Investors Who Bought Akcea Therapeutics (NASDAQ:AKCA) Shares A Year Ago Are Now Down 13% Simply Wall St. +5.94%
Jun-20-19 04:38PM  Akcea and Ionis Announce Upcoming Data Presentations at the 2019 Peripheral Nerve Society Annual Meeting GlobeNewswire
May-28-19 07:00AM  Akcea Therapeutics to Present at Upcoming Investor Conferences GlobeNewswire
May-14-19 03:51PM  Ionis Pharmaceuticals Is 40% of the Way There Motley Fool
May-08-19 11:23PM  Akcea Therapeutics, Inc. (AKCA) Q1 2019 Earnings Call Transcript Motley Fool
06:55PM  Akcea Therapeutics (AKCA) Q1 Earnings and Revenues Lag Estimates Zacks
05:51PM  Akcea Therapeutics: 1Q Earnings Snapshot Associated Press
04:05PM  Akcea Reports Financial Results and Highlights for First Quarter 2019 GlobeNewswire
May-07-19 08:21PM  Can Pfizer Leap Over the Competition With This Potential Blockbuster? Motley Fool -5.05%
04:05PM  New Long-Term TEGSEDI Safety and Efficacy Data Featured as an Oral Presentation at 2019 American Academy of Neurology Annual Meeting (AAN) GlobeNewswire
08:41AM  Akcea and Ionis Announce Approval of WAYLIVRA® (volanesorsen) in the European Union GlobeNewswire
May-02-19 07:05AM  Akcea Announces Upcoming Data Presentations at the 2019 American Academy of Neurology Meeting (AAN.19) GlobeNewswire
May-01-19 10:33AM  Akcea Therapeutics (AKCA) Earnings Expected to Grow: Should You Buy? Zacks
Apr-26-19 12:18PM  Heres What Hedge Funds Think About Akcea Therapeutics, Inc. (AKCA) Insider Monkey
Apr-25-19 10:34AM  Akcea Therapeutics (AKCA) Earnings Expected to Grow: What to Know Ahead of Q1 Release Zacks
Apr-24-19 07:00AM  Akcea Therapeutics to Hold First Quarter 2019 Financial Results Webcast GlobeNewswire
Mar-15-19 04:05PM  Akcea and Ionis Announce Upcoming Data Presentations at the 2019 American College of Cardiology Meeting (ACC.19) GlobeNewswire
Mar-08-19 01:10PM  Why Akcea Therapeutics, Inc. (NASDAQ:AKCA) Is A Financially Healthy Company Simply Wall St.
Mar-06-19 08:20AM  Report: Developing Opportunities within Sarepta Therapeutics, Sally Beauty, Danaher, Ellie Mae, BioCryst Pharmaceuticals, and Akcea Therapeutics Future Expectations, Projections Moving into 2019 GlobeNewswire
Mar-04-19 03:46PM  Ionis Pharmaceuticals Funds Its Pipeline of More Than 40 Drugs Motley Fool
Mar-01-19 08:44AM  EU committee approves Akcea-Ionis drug for rare genetic disease Reuters
07:45AM  Akcea and Ionis Receive Positive EU CHMP Opinion for WAYLIVRATM (volanesorsen) GlobeNewswire
Feb-28-19 07:00AM  Akcea® Recognizes Rare Disease Day Through Efforts to Increase Awareness of Hereditary Transthyretin Amyloidosis and Familial Chylomicronemia Syndrome GlobeNewswire +8.20%
Feb-27-19 02:35PM  Here's Why Ionis Pharmaceuticals Jumped Higher Today Motley Fool +8.45%
Feb-26-19 08:00PM  Akcea Therapeutics, Inc. (AKCA) Q4 2018 Earnings Conference Call Transcript Motley Fool -9.12%
04:05PM  Akcea Reports Financial Results and Highlights for Fourth Quarter and Year End 2018 GlobeNewswire
02:30PM  Akcea Therapeutics, Inc. to Host Earnings Call ACCESSWIRE
Feb-25-19 01:15AM  AKCEA-APO(a)-LRx Advances as Leading Pharmaceutical Company Exercises Option to License GlobeNewswire +16.72%
Feb-20-19 07:00AM  Akcea Therapeutics to Present at Upcoming Investor Conferences GlobeNewswire
Feb-15-19 07:45AM  Detailed Research: Economic Perspectives on Yelp, Jabil, SBA Communications, comScore, AVX, and Akcea Therapeutics What Drives Growth in Today's Competitive Landscape GlobeNewswire
Akcea Therapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing drugs to treat patients with serious and rare diseases in the United States and internationally. The company offers TEGSEDI, which is designed to reduce the production of transthyretin protein. It develops WAYLIVRA, which has completed Phase III clinical study for the treatment of familial chylomicronemia syndrome; and that is in Phase III clinical study for the treatment of familial partial lipodystrophy. The company also develops AKCEA-APO(a)-LRx, which has completed Phase IIb clinical study for treating patients suffering with hyperlipoproteinemia; AKCEA-ANGPTL3-LRx that has completed Phase IIb clinical study for the treatment of multiple lipid disorders; and AKCEA-APOCIII-LRx, which is in Phase II study for the treatment of cardiovascular disease due to elevated triglyceride levels, as well as AKCEA-TTR-LRx to treat the broad population of patients with hereditary and wild-type forms of transthyretin amyloidosis. It has strategic collaboration with Novartis Pharma AG and PTC Therapeutics International Limited. The company was incorporated in 2014 and is headquartered in Boston, Massachusetts. Akcea Therapeutics, Inc. operates as a subsidiary of Ionis Pharmaceuticals, Inc.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Patterson Joshua F.General CounselMar 23Sale11.763353,93814,614Mar 25 04:44 PM
Jenne KyleChief Commercial OfficerMar 23Sale11.757799,15352,732Mar 25 04:43 PM
O'Dea LouisChief Medical OfficerMar 23Sale11.753,19837,57961,602Mar 25 04:42 PM
McDevitt DamienChief Executive OfficerMar 23Sale11.759,417110,649245,783Mar 25 04:41 PM
Goldberg Jeff MarcChief Operating OfficerSep 26Option Exercise6.96421,4322,932,747305,560Sep 30 09:26 PM
Soteropoulos PaulaChief Executive OfficerSep 26Option Exercise7.052,061,86114,538,2541,711,079Sep 30 05:52 PM
Boyce SarahPresidentJul 15Sale23.521,81942,78319,888Jul 17 04:52 PM
Soteropoulos PaulaChief Executive OfficerApr 08Option Exercise6.481,78711,5801,787Apr 09 06:59 PM
Goldberg Jeff MarcChief Operating OfficerApr 08Option Exercise6.4820,000129,60022,880Apr 09 07:00 PM
Goldberg Jeff MarcChief Operating OfficerApr 08Sale31.7220,000634,4182,880Apr 09 07:00 PM
Soteropoulos PaulaChief Executive OfficerApr 08Sale32.171,78757,4800Apr 09 06:59 PM